

Fax No : 91 (22) 2678 4391 / 5198 Tel. No. : 91 (22) 66888333 Website : http://www.unichemlabs.com CIN : L99999MH1962PLC012451.

Registered & Corporate Office : Unichem Bhavan, Prabhat Estate, S. V. Road, Jogeshwari (West), Mumbai-400102, INDIA.

March 8, 2017 Ref: Stock-exchage/2016-17

Department of Corporate Services Bombay Stock Exchange Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Mr. Hari K Asst. Vice President – Operations National Stock Exchange of India Ltd Exchange Plaza, Bandra – Kurla Complex Bandra (East), Mumbai – 400 051

Dear Sir,

Ref: BSE Scrip Code -506690 : NSE Symbol – UNICHEMLAB Sub: Disclosures under Reg. 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed herewith the press release pertaining to receipt of ANDA approval from United States Food and Drug Administration (U.S. FDA) for Rizatriptan Benzoate ODT 5mg & 10mg and Rizatriptan Benzoate Tablets USP, 5mg & 10mg which are therapeutically equivalent to Maxalt – MLT Tablets 5mg & 10mg and Maxalt Tablets 5mg 10mg of Merck & Company, Inc.

Please take this on record.

Thank you,

Yours Faithfully, For UNICHEM LABORATORIES LIMITED

V. a. Ma 1000

NEEMA THAKORE *Head – Legal & Company Secretary*

ZAJayesh Udeshi\Press Release\20170308\stockey.doc



UNICHEM LABORATORIES LIMITED

Unichem Bhavan Prabhat Estate, Off S.V.Road, Jogeshwari (West), Mumbai - 400 102. Tel. No: +91 (22) 66 888 333 Fax. No: +91 (22) 267 843 91/ 5198 CIN: L99999MH1962PLC012451

Press Release

Mumbai, Wednesday March 8, 2017

Unichem Laboratories receives ANDA approval from USFDA for Rizatriptan Benzoate ODT & Rizatriptan Benzoate Tablets USP

Unichem Laboratories Limited is pleased to announce that it has received ANDA approval from the United States Food and Drug Administration (USFDA) for Rizatriptan Benzoate ODT 5mg & 10mg and Rizatriptan Benzoate Tablets USP, 5mg & 10mg which are therapeutically equivalent to Maxalt – MLT Tablets 5mg & 10mg and Maxalt Tablets 5mg 10mg of Merck & Company, Inc.

Rizatriptan Benzoate Tablets USP, 5mg & 10mg and Rizatriptan Benzoate ODT USP, 5mg & 10mg; is a serotonin (5-HT) 1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine in adults and in pediatric patients 6 to 17 years of age.

The product will be commercialized from Unichem's Goa plant. Active Pharmaceutical Ingredient will also be made in house at Roha API Plant.



About Unichem Laboratories Limited

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche therapy areas of cardiology, neurology, orthopedics and anti-infectives. The company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms. More information about the company can be found at <u>www.unichemlabs.com</u>

For more information please contact:

Ms. Neema Thakore Ph: +91-22-66888 404 E-mail: neema.thakore@unichemlabs.com Mr. Rakesh Parikh/ Mr. Monish Shah Ph: +91-22-66888 414 Ph: +91-22-66888 509 E-mail: rparikh@unichemlabs.com monish.shah@unichemlabs.com

Disclaimer: This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.